At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 64 enrolled
Drug / intervention
Sublingual immunotherapyother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Serum MicroRNAs 223 and 146a in Allergic Rhinitis Patients: Correlation With Disease Severity and Their Role as Biomarkers for Efficacy of Sublingual Immunotherapy
In Brief
A Phase 3 clinical trial evaluating Sublingual immunotherapy for Effects of Immunotherapy. Completed, enrolled 64 participants across 1 site.
Detailed Summary
The aim of the study is: * to evaluate the serum levels of miR-223 and miRNA146a and to assess their correlation with disease severity in allergic rhinitis patients and their role as biomarkers for efficacy of sublingual immunotherapy. * also to find if high sensitivity CRP can be an easy non-expensive test for diagnosis and follow up of allergic rhinitis patients.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEffects of Immunotherapy
CountriesEgypt
Collaborators--
Timeline
Phase 3CompletedFinished
20222023202420252026
First PostedMar 2021
Enrollment StartJul 2021
Primary CompletionSep 2022
Study CompletionOct 2022
TodayJul 2026
First PostedMar 24, 2021
Enrollment StartJul 27, 2021
Primary CompletionSep 10, 2022
Study CompletionOct 10, 2022
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 5.3 years ago
Interventions
Sublingual immunotherapyother
Sublingual immunotherapy give to allergic rhinitis patients for treatment